Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis?

被引:29
|
作者
Jost, Jeremy [1 ]
Bahans, Claire [2 ]
Courbebaisse, Marie [4 ]
Tu-Anh Tran [5 ]
Linglart, Agnes [6 ]
Benistan, Karelle [7 ]
Lienhardt, Anne [2 ]
Mutar, Hadile [2 ]
Pfender, Elodie [3 ]
Ratsimbazafy, Voa [1 ]
Guigonis, Vincent [2 ,8 ]
机构
[1] Com HME Rech Clin Ctr Hosp Univ, Pharm, F-87000 Limoges, France
[2] Com HME Rech Clin Ctr Hosp Univ, Univ Limoges,Ctr Hosp Univ Limoges,INSERM, Inst Epidemiol Neurol & Neurol Trop,UMRS 1094, Ctr Natl Rech Sci Federat Rech Genom Environm Imm, F-87000 Limoges, France
[3] Ctr Hosp Univ, Ctr Invest Clin, F-87000 Limoges, France
[4] Hop Europeen Georges Pompidou, AP HP, Dept Physiol, F-75000 Paris, France
[5] Ctr Hosp Univ Nimes, Pediat, F-30000 Nimes, France
[6] AP HP, Ctr Reference Malad Rare Metab Phosphocalc & Plat, F-94270 Le Kremlin Bicetre, France
[7] Hop Raymond Poincare, Genet Med, F-92380 Garches, France
[8] Univ Limoges, CNRS, UMR 7276, F-87000 Limoges, France
来源
关键词
OF-THE-LITERATURE; UREMIC ARTERIOLOPATHY; CALCIPHYLAXIS; GALNT3; MANAGEMENT; PHOSPHATE; MUTATION; ACETAZOLAMIDE; ACIDOSIS; THERAPY;
D O I
10.1210/jc.2016-1087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia hyperostosis syndrome (HHS) are rare diseases characterized by hyperphosphatemia and ectopic calcifications or recurrent episodes of diaphysitis. In the setting of metabolic or inflammatory diseases, recent data suggest that systemic administration of sodium thiosulfate (STS) could be effective in the treatment of ectopic calcifications but may also be poorly tolerated (digestive symptoms, metabolic acidosis). Our group developed a topical formulation of STStotreat ectopiccalcifications locally, therefore limiting patient exposure to the drug and its adverse effects. Objective: We aimed at describing efficacy and tolerance fora topical formulation of STS in treated patients. Design: We performed a retrospective study wherein clinical, radiological, and biological data before and after the application of the topical STS treatment were collected and analyzed. Patients or Other Participants: Three patients admitted to 3 different hospitals with an ectopic calcification secondary to HFTC or HHS were treated with topical STS. Intervention: The topical STS was applied daily by the patients. Results: A significant clinical and radiological decrease of ectopic calcifications was observed after at least 5 months of treatment. The STS treatment was well tolerated and no clinical or biological side effects were observed. Conclusion: Topical STS appears to be a promising treatment for ectopic calcifications secondary to HFTC or HHS.
引用
收藏
页码:2810 / 2815
页数:6
相关论文
共 50 条
  • [21] Bone Involvement in Hyperphosphatemic Familial Tumoral Calcinosis: A New Phenotypic Presentation
    Freedman, J. Daniel
    Novak, Rostislav
    Morag, Sharon Bratman
    Avitan-Hersh, Emily
    Nikomarov, David
    RAMBAM MAIMONIDES MEDICAL JOURNAL, 2021, 12 (03):
  • [22] Familial hyperphosphatemic tumoral calcinosis: A rare case report from Syria
    Al Abdulrahman, Balkis
    Eed, Hiba
    Kurdy, Rama
    Alwadi, Yazan
    Alcheikh, Salwa
    CLINICAL CASE REPORTS, 2024, 12 (09):
  • [23] Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism
    Papadakis, JT
    Patrikarea, A
    Digenis, GE
    Stamatelou, K
    Ntaountaki, I
    Athanasopoulos, V
    Tamvakis, N
    NEPHRON, 1996, 72 (02): : 308 - 312
  • [24] Dementia associated with hyperphosphatemic tumoral calcinosis
    Beck, DA
    Gray, L
    Lyles, KW
    CLINICAL NEUROLOGY AND NEUROSURGERY, 1998, 100 (02) : 121 - 125
  • [25] Vertebral involvement in hyperphosphatemic tumoral calcinosis
    Blay, P
    Fernández-Martínez, JM
    Díaz-López, B
    BONE, 2001, 28 (03) : 316 - 318
  • [26] Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis
    Alan Yancovitch
    Dov Hershkovitz
    Margareta Indelman
    Peter Galloway
    Margo Whiteford
    Eli Sprecher
    Esra Kılıç
    Journal of Bone and Mineral Metabolism, 2011, 29 : 621 - 625
  • [27] Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
    Puar, Akshan
    Donegan, Diane
    Helft, Paul
    Kuhar, Matthew
    Webster, Jonathan
    Rao, Megana
    Econs, Michael
    AACE CLINICAL CASE REPORTS, 2022, 8 (05): : 217 - 220
  • [28] Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis
    Yancovitch, Alan
    Hershkovitz, Dov
    Indelman, Margareta
    Galloway, Peter
    Whiteford, Margo
    Sprecher, Eli
    Kilic, Esra
    JOURNAL OF BONE AND MINERAL METABOLISM, 2011, 29 (05) : 621 - 625
  • [29] Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis
    Requena, Sheila
    Santos-Juanes, Jorge
    Morales, Patricia
    Gomez, Carlos
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (01) : E75 - E77
  • [30] Hyperphosphatemic Familial Tumoral Calcinosis Hidden in Plain Sight for 73 Years: A Case Report
    Lee, Alisa E.
    Hartley, Iris R.
    Roszko, Kelly L.
    Vanek, Chaim
    Gafni, Rachel I.
    Collins, Michael T.
    FRONTIERS IN DENTAL MEDICINE, 2021, 2